The antibacterial activity and mechanism of a novel peptide MR-22 against multidrug-resistant .

Introduction: Bacterial infections have become serious threats to human health, and the excessive use of antibiotics has led to the emergence of multidrug-resistant (MDR) bacteria. is a human bacterial pathogen, which can cause severe infectious. Antimicrobial peptides are considered the most promising alternative to traditional antibiotics.

Antimicrobial peptide DvAMP combats carbapenem-resistant Acinetobacter baumannii infection.

Carbapenem-resistant Acinetobacter baumannii (CRAB), an important opportunistic pathogen, is a major cause of healthcare-associated infections. The polymyxins (colistin and polymyxin B) are the last line of defense in the treatment of CRAB infections, and there is an urgent need to develop novel alternative therapeutic strategies. In this study, we found that the antimicrobial peptide DvAMP exhibited satisfactory antibacterial and antibiofilm activity against CRAB.

Novel antimicrobial peptide DvAMP serves as a promising antifungal agent against Cryptococcus neoformans.

Cryptococcus neoformans is an important opportunistic human fungal pathogen that causes cryptococcosis in immunocompromised patients. However, the number of drugs for the treatment of cryptococcosis is restricted, and the development of novel antifungal drugs and innovative strategies for the treatment of cryptococcosis is urgently needed. In this study, we validated that DvAMP is a novel antimicrobial peptide with antimicrobial activity and that it was obtained by pre-screening from the UniProt database of more than three million unknown functional sequences based on the quantitative structure-activity relationships (QSARs) protocol (http://www.

[Identification of the target site of antimicrobial peptide AMP-17 against ].

is one of the major causes of invasive fungal infections and a serious opportunistic pathogen in immunocompromised individuals. The antimicrobial peptide AMP-17 has prominent anti- activity, and proteomic analysis revealed significant differences in the expression of cell wall () and oxidative stress () genes upon the action of AMP-17 on . , suggesting that AMP-17 may exert anti-.

The Antimicrobial Peptide AMP-17 Derived from Inhibits Biofilm Formation and Eradicates Mature Biofilm in .

The biofilm formation of represents a major virulence factor during candidiasis. Biofilm-mediated drug resistance has necessitated the search for a new antifungal treatment strategy. In our previous study, a novel antimicrobial peptide named AMP-17 derived from was confirmed to have significant antifungal activity and suppress hyphal growth greatly in .

Identification and functional characterization of , a novel gene involved in both azoles susceptibility and hypha development in .

Azole resistance is becoming increasingly serious due to the frequent recurrence of fungal infections and the need for long-term clinical prevention. In our previous study, we discovered with an unknown function by TMT quantitative proteomics technology after fluconazole (FLC) treatment of . In this study, we created the target gene deletion strain using CRISPR-Cas9 editing technology to see if regulates azole sensitivity.